Tag Archive for: drug discovery

Pharmacelera raises €6M to expand in U.S. and build out its high speed, high accuracy, deep tech drug discovery platform

/in

Round led by Heran Partners and joined by Clave Capital, Inveready and Bio&Tech Smart Capital Financing will enable Pharmacelera to build ongoing relationships with major pharma and biotech customers in the US Pharmacelera’s platform scours vast chemical ‘exaSpace’ accurately for novel molecules  Barcelona, Spain, February 18, 2026 – Pharmacelera, a deep tech company applying Quantum […]

Read more

Resolve M Therapeutics exits from stealth

/in

Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression. Cambridge, MA, USA, January 22, 2026 – Resolve M Therapeutics, Inc., the biotech aiming to build the world’s first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its […]

Read more

DaltonTx raises £4 million seed financing to build the intelligence backbone of drug discovery

/in

DaltonTx, a UK-based technology company, today announces its exit from from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster. AI offers pharma a unique opportunity to discover medicines more effectively and […]

Read more

Hot topic: Where is AI having the biggest impact in healthcare right now?

/in

The big buzz around AI in healthcare is the potential it holds to identify and even create new drugs. “AI drug discovery” is the great new hope. And – despite critics awkwardly pointing out that no AI-generated drugs have yet been approved by any regulator, and vanishing few appear to be close to that finishing […]

Read more

Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups

/in

Delivers high-performing AI infrastructure through NVIDIA DGX Cloud Lepton to portfolio companies, creating a powerful competitive advantage in $100B+ life sciences market BioCorteX, Bioptimus, Cure51, and Latent Labs among first cohort of startups to gain GPU capacity credits, helping position Europe at forefront of AI-driven drug discovery revolution PARIS, France – June, 11, 2025 – […]

Read more
© Optimum Strategic Communications.